1. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy
by Alfonso Quintás-Cardama, Hagop Kantarjian, Dan Jones, Jianqin Shan, Gautam Borthakur, Deborah Thomas, Steven Kornblau, Susan O'Brien, and Jorge Cortes
Blood
Volume 113(25):
June 18, 2009
©2009 by American Society of Hematology

2. Overall, transformation-free, and event-free survival of 258 patients receiving imatinib therapy.
Alfonso Quintás-Cardama et al. Blood 2009;113:
©2009 by American Society of Hematology

3. Probability of achieving a complete cytogenetic response versus developing an event for patients not in complete cytogenetic response.
Probability of achieving a complete cytogenetic response versus developing an event for patients not in complete cytogenetic response. (A) After 3 months of imatinib therapy. (B) After 6 months of imatinib therapy. (C) After 12 months of imatinib therapy.
Alfonso Quintás-Cardama et al. Blood 2009;113:
©2009 by American Society of Hematology